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ABSTRACT
Objective: The objective of this systematic review is to determine whether or not Epidermal
Growth Factor Vaccine also known as CimaVax-EGF is more effective at improving survival
than best supportive care or other therapies in patients with non-small cell lung cancer.
Study Design: Systematic review of two randomized control trials (RCTs) and one
observational/before and after study published after the year 2007.
Data Sources: All articles were published in English in peer reviewed journals and were searched
for personally by me, the author, via PubMed and Embase. Articles selected were only those that
were published after 2007, were relevant to my clinical question and addressed patient oriented
outcomes that mattered.
Outcomes Measured: Primary outcome measured was overall survival as estimated in months or
measured in years. Secondary outcome measured was safety as estimated by percent of patients
experiencing any adverse effects and/or specific adverse reactions.
Results: Both Rodriguez et al and Vinageras et al claim that Epidermal Growth Factor vaccine
improves overall survival in patients with stage IIIB/IV NSCLC based on the results of their
RCTs (Rodriguez et al 343 patients total assessed for efficacy, p = 0.036, 5 year survival in
vaccinated 16.62% vs control 6.2% NNT = 10, Vinageras et al 74 patients total assessed for
efficacy, p = 0.0124, 1 year survival in vaccinated 67% vs. control 33% NNT = 3). Kananathan
made no claims about efficacy but claimed survival rates indicated the need for a randomized
control trial to determine efficacy (23 patients assessed for efficacy, 1 year survival = 91% 5 year
survival = 9%). All three studies found the vaccine to be safe and well tolerated.
Conclusions: Although both RCTs claim the EGF vaccine improves survival in Stage IIIB/IV
NSCLC patients, risk of bias in study design (not blinded, use of other therapies) and quality of
data reported (not reporting some censored patients, overlap of CIs) limit efficacy claims as does
the number of studies reviewed. Large double blinded studies are needed to study efficacy.
Key Words: Epidermal Growth Factor (EGF) vaccine and non-small cell lung cancer, CimaVaxEGF and non-small cell lung cancer
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INTRODUCTION
Lung cancer is the leading cause of cancer death in the world, with non-small cell lung
cancer (NSCLC) accounting for 85% of lung cancers in the United States.1,2
In 2017, the estimated number of new cases of NSCLC are 222, 500 and the estimated
number of deaths from NSCLC are 155, 870.3 An estimated 13.6 billion dollars were spent
nationally for lung cancer in 2016.4 In 2006, nearly half a million hospital stays included lung
cancer as a diagnosis with almost 28% citing lung cancer as the primary reason for the stay.5
The cause of NSCLC (and lung cancer in general) is thought to be largely due to
environmental exposure to carcinogens with individual susceptibility to carcinogens and
presence or absence of protective factors playing a minor role. Cigarette smoking in particular
accounts for about 85% of lung cancers in the U.S.2
Surgical resection of NSCLC tumors is typically considered first line treatment,
particularly in early stages. Radiation therapy and/or chemotherapy pre or post operatively or as
part of first line treatment for late stages are also commonly used. Prophylactic cranial irradiation
is used to reduce incidence of brain metastases. Identification of mutations, particularly in the
EGFR, MAPK, PI3K signaling pathways, has led to targeted therapy that addresses
abnormalities in these pathways and associated drug resistance.3
Some of the mentioned treatments may in some cases provide a cure, particularly in early
stages, and may in some cases prolong survival, however 1 year survival for patients with
NSCLC with wild type tumors was 35% and 5 year survival was 5%.6 Epidermal growth factor
has been shown to promote cancer cell growth and proliferation and patients with NSCLC with
overexpression of this factor have been shown to have a poorer prognosis. A vaccine known as
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the Epidermal Growth Factor vaccine has therefore been developed with the goal of prolonging
survival by inducing autoimmunity against this self-protein.6
This paper evaluates two randomized control trials (RCTs) and one observational/before
and after study investigating the efficacy of Epidermal Growth Factor Vaccine as a treatment for
NSCLC as measured by overall survival.
OBJECTIVE
The objective of this systematic review is to determine whether or not Epidermal Growth
Factor Vaccine also known as CimaVax-EGF is more effective at improving survival than best
supportive care or other therapies in patients with non-small cell lung cancer.
METHODS
Criteria used for selection of studies were as follows: addressed the population of patients
with NSCLC, used Epidermal Growth Factor (EGF) vaccine also known as CimaVax-EGF as an
intervention, used supportive care and/or other therapies as comparisons, measured overall
survival, and were either randomized control trials or observational/before and after studies.
Key words used for searching articles were Epidermal Growth Factor (EGF) vaccine and
non-small cell lung cancer, CimaVax-EGF and non-small cell lung cancer. All articles searched
were published in English and all articles were published in peer-reviewed journals. The search
databases used were PubMed and Embase. Articles were selected based on their relevance to my
clinical question and if they included patient oriented outcomes (POEMs).
The inclusion criteria for selection were RCTs or observational/before and after studies
published after 2007. The exclusion criteria for selections were studies published 2007 or earlier,
studies that did not measure POEMs.
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Statistics reported in the articles were median survival estimates, 95% CIs, p-values,
hazard ratios. Statistics calculated by author were RBI, ABI, NNT, RRI, ARI, NNH.6,7,8
See Table 1 for demographics and characteristics of included studies.
Table 1: Demographics and Characteristics of Included Studies
Study
and
Type
Rodrigue
z
20167
RCT

Vinagera
s 20088

# of pts,
Age in
years
 405 pts
 Ages not
listed but
articles
mentions
pts
matched
for age

 80 pts
 Median
age 55.5

RCT

Kananath
an
20159
Observati
onal/
Before
and After

 23 pts
 Median
age 55.18

Inclusion Criteria

Exclusion
Criteria

W
/D

Interventions

 Patients 18 or older with histologically
or cytologically proven stage IIIB/IV
NSCLC and an ECOG performance
status of 0-2
 Patients with all NSCLC subtypes and
life expectancy of at least 3 months
 Hemoglobin values ﹥90 g/L
 Leukocytes count ≥ 3.0 x 109 /L
 Platelet count ≥ 150 x 109 /L
 Aspartate aminotransferase and alanine
aminotransferase up to 2.5X the upper
institutional limit
 Creatinine up to 2X the upper
institutional reference value
 Received 4-6 cycles of platinum based
chemotherapy ( mostly
cisplatin/carboplatin in combination
with vinblastine, etoposide or
paclitaxel)
 Had stable disease or objective disease
 Pts older than 18 with histologically or
cytologically proven non small cell
lung cancer at stages IIIB/IV
 ECOG performance status of at least 2
 Adequate bone marrow reserve
 WBC count of at least 3,000 per
microliter
 Platelet count of at least 100,000 per
microliter
 Hemoglobin of at least 10 g/dL
 Life expectancy of longer than 3
months
 Normal creatinine, bilirubin, and
transaminase according to each
institutional standards
Patients with stage III/IV non small cell
lung cancer

Not listed
in study

54

2.4 mg of Epidermal
Growth Factor (EGF)
vaccine given IM at four
injection sites (two
deltoid and two gluteal)
every 2 weeks for 4
doses and then monthly
thereafter as well as best
supportive care with 200
mg/m2
cyclophosphamide given
IV 72 hrs prior to first
immunization

 Pregnanc
y or
lactation
 Secondar
y
malignan
cies
 History
of
hypersen
sitivity
to
foreign
proteins

6

 EGF vaccine on days
1, 7, 14, 28 and
monthly after with 200
mg/m2
cyclophosphamide
given 3 days before 1st
dose
 External beam
radiotherapy for
palliative care
 Supportive care if
required

Not listed

1

Four IM injections of
Cimavax(EGF vaccine)
given day 0, 14, 28, and
every 28 days thereafter
with 300 mg IV
cyclophosphamide given
72 hrs prior to first
vaccination
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OUTCOMES
The primary outcome measured in all three studies was overall survival, estimated in
months by the Kaplan Meier method in the Rodrigues et al and Vinageras et al studies, 1 year
survival for the Vinageras et al and Kananathan et al study studies, 2,3,4 year survival for the
Kananathan et al study and 5 year survival by the Rodrigues et al and Kananathan et al studies.
Safety was a secondary outcome measured as estimated by percentage of patients experiencing
any and/or specific adverse events.6,7,8
RESULTS
Description of Studies
Rodriguez et al conducted a randomized control trial that started with 405 patients with
stage IIIB and IV NSCLC, 270 of which were enrolled in the vaccination arm, 135 of which
were enrolled in the control arm. Patients in the control arm were treated with best supportive
care. The two arms were matched for gender, ethnic origin, smoking history, ECOG score,
disease stage, tumor histology, and response to first line treatment. Of the 270 patients enrolled
in the vaccination arm, 219 received four doses of the vaccine as per protocol (regimen necessary
for vaccine induction) and were assessed for efficacy. In the control arm, 124 were assessed for
efficacy. Reasons for dropout included death prior to completion of induction period, rapid
worsening of performance status, other comorbidities as well as schedule violations and consent
withdrawal.6
Vinageras et al conducted a randomized control trial that initially involved 80 patients
with stage IIB and IV NSCLC, 40 of which were enrolled in the vaccination arm and the other
40 of which enrolled in the control arm. Patients in the control arm were treated with best
supportive care. External beam radiotherapy was performed for symptomatic relief in both the
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vaccine and control arm. The two arms were matched for age, gender, race, ECOG score, disease
stage, tumor histology, prior treatment and response to chemotherapy. Six patients were removed
from assessment, three from the vaccine arm and three from the control arm. Reason for
nonassessibility was given as noncompliance with entry criteria and refusing participation after
random assignment.7
Kananathan et al conducted an observational/before and after study involving 23 patients
with stage III or IV NSCLC all of which were vaccinated with CIMAvax (EGF vaccine). Age,
ethnicity, gender varied among the group with a disproportionate number of male patients (16
males to 7 females) and disproportionate number of Malaysian individuals (18 Malaysian
compared to 2 Indonsesian, 2 Australian, and 1 Chinese patient). Additionally, patients were on
different first line therapies simultaneously while receiving vaccination, with chemotherapy
being the most common first line therapy (15 patients).8
Risk of Bias in Included Studies
Both the Rodriguez et al and Vinageras et al studies were controlled trials in which the
control and treatment groups were similar in terms of demographics, and assignment of patients
to treatments was randomized, however, the randomization allocation was not concealed from
those enrolling in the study, clinicians and study workers were not kept blind to treatment which
introduces the possibility of bias. The losses to follow up were less than 20%, and follow up of
patients was sufficient long.6,7 Kananathan et al was an observational/before and after study.
Men compared to women and individuals of Malaysian descent were disproportionally
represented which are significant concerns for bias.8
Cyclophosphamide was given prior to first vaccine dose in the vaccine arm in both the
Rodriguez et al and Vinageras et al studies but not given in the control group.6,7. In the
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Rodriguez et al study, sixteen patients in the vaccine arm and nine patients in the control arm
received other therapies with one patient in each arm receiving a drug known to increase survival
in advanced stage NSCLC.6 A large number of patients in the Kananathan et al study received a
variety of different first line treatments in addition to vaccination.8 These confound any efficacy
claims by the study authors.
Safety
Of the 270 patients enrolled in the vaccine arm in Rodrigues et al, 246 received at least
one vaccine dose and were thus considered the safety population and used for safety analysis
while 132 out of 135 patients in the control group were used for safety analysis (three patients in
the control group withdrew consent). In the vaccine arm, 195 patients (78.3%) reported any
adverse event while in the control arm, 73 patients (55.3%) reported any adverse event.6 The
relative risk increase (RRI) is 0.416, the absolute risk increase (ARI) is 0.230, and the number
need to harm (NNH) is 4 (see Table 2). The most common adverse events reported were
injection site reactions, 46.6% in vaccine arm vs 0% in control arm, fever 36.5% in vaccine arm
vs 7.6% in the control arm, dyspnea 31.7% in the vaccine arm vs 28.8 % in the control arm,
vomiting 23.3% in the vaccine arm and 3.8% in the control arm, and headache 22.5% in the
vaccine arm vs 6.8% in the control arm.6
Of the 40 patients enrolled in the vaccine arm in the Vinageras et al study, 40 were
analyzed for safety and of the 40 patients enrolled in the control arm, 40 were analyzed for
safety. The incidence of any adverse event in the vaccine and in the control arm was not
reported, however the most common reported symptoms were fever, 25% in the vaccine arm and
7.5% in the control arm, headache, 25% in the vaccine arm and 10% in the control arm, asthenia
20% in the vaccine arm and 18% in the control arm, tremor 18% in the vaccine arm and 0% in
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the control arm, and chills 18% in the vaccine arm and 0% in the control arm.7 The relative risk
increase (RRI) for fever, the most common side effect, is 2.33, the absolute risk increase (ARI) is
0.175, and the number need to harm (NNH) is 5 (see Table 2).
Kananathan et al simply report pain and chills with rigors as being the most common side
effects.8
Table 2 – Relative Risk Increase, Absolute Risk Increase and Numbers Needed to Harm as
Determined by Percent of Patients Experiencing One or More Adverse Events
Study

Control Event
Rate (CER)

Rodriguez et al
Vinageras et al

0.553
0.075

Experimental
Event Rate
(EER)
0.783
0.25

Relative risk
increase (RRI)

Absolute risk
increase (ARI)

Number needed
to Harm (NNH)

0.416
2.33

0.230
0.175

4
5

Efficacy
In the study conducted by Rodriguez et al, in the per protocol population, median survival
was 12.43 months (95% CI 10.42-14.45) in the vaccine arm and 9.43 months (95% CI 7.5311.33) in the control arm. Five year survival was 16.62% in the vaccine arm and 6.2% in the
control arm. The authors conducted a standard, unweighted log-rank test on survival data and
found HR 0.77, 95% CI 0.61-0.98, p = 0.036 and as such the survival difference was considered
statistically significant.6 Using 5 year survival for the control arm as the control event rate and 5
year survival for the vaccine arm as the experimental event rate, relative benefit increase (RBI)
was 1.682, absolute benefit increase (ABI) was 0.104, and number needed to treat was 10 (refer
to Table 3).
Of note, patients with higher than median serum Epidermal Growth Factor (EGF)
concentrations that were vaccinated were found to have a statistically significant survival
advantage over controls with the same EGF concentrations (HR 0.41 95% CI 0.25-0.67 P=
0.0001). Median survival for this subset of vaccinated patients was 14.66 months (95% CI 8.3420.98) and 8.63 months for this subset of controls ( 95% CI 1.67-15.59). Five year survival in
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this subset of vaccinated patients was 23% while 5 year survival in this subset of controls was
0%. Additionally patients who were determined to have a good antibody response to the vaccine
after the completion of the induction period were found to have a statistically significant survival
benefit when compared to controls (median survival was 14.90 months in the vaccine arm vs
8.86 months for the control arm (HR 0.638 95% CI 0.44-0.92 p = 0.017)).6
In the study conducted by Vinageras et al, in the vaccine arm, median survival was 6.47
months (mean survival 12.73 months) and in the control arm, median survival was 5.33 months
(mean survival 8.52 months). These changes were not significant. A significant difference in
survival however was found in patients 60 years old or younger. In vaccinated patients 60 years
old or younger, median survival was 11.57 months (mean survival 18.53 months) while in the
control arm, median survival was 5.33 months (mean survival was 7.55 months, P = 0.0124).
One year survival rate was 67% for all vaccinated patients and 33% for controls. One year
survival for patients 60 years old or younger was 75% in the vaccine arm and 25% for controls.7
Using 1 year survival in all age groups for the control arm as the control event rate and 1 year
survival for the vaccine arm in all age groups as the experimental event rate, relative benefit
increase (RBI) as 1.03, absolute benefit increase (ABI) was 0.34, and number needed to treat was
3 (refer to Table 3).
Of note, just as in Rodriquez et al, there was a survival advantage found in vaccinated
patients determined to have a good antibody response compared to controls (median survival in
vaccine arm was 11.7 months (mean 19.47 months) while median survival in control arm was
5.33 months (mean 8.52 months). Additionally there was a survival advantage in vaccinated
patients with good antibody response compared to vaccinated patients with poor antibody
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response ( median survival in vaccinated patients with poor antibody response 3.6 months (mean
4.49 months)).7
In the study conducted by Kananathan et al, median survival was 21 months, mean
survival was 30.2 months. Survival rate was 91% at 1 year, 43% at 2 years, 30% at 3 years, and
9% at 5 years.8
Table 3 – Relative Benefit Increase, Absolute Benefit Increase and Numbers Needed to Treat as
Determined by 5 year and 1 year survival
Control Event
Rate (CER)
Study
Rodriguez et al*
Vinageras et al**

0.062
0.33

Experimental
Event Rate
(EER)
0.1662
0.67

Relative benefit
increase (RBI)

Absolute benefit
increase (ABI)

Number needed
to Treat (NNT)

1.680
1.03

0.104
0.34

10
3

*Event is 5 year survival rate in decimal form
**Event is 1 year survival rate in decimal form
DISCUSSION
Summary of Main Findings
Rodriquez et al found that there was a statistically significant survival advantage for
patients vaccinated with the EGF vaccine (p = 0.036) while Vinageras et al found a statistically
significant survival advantage in vaccinated patients only in patients 60 years old or younger.
Furthermore, Rodriguez et al found a statistically significant advantage in survival for vaccinated
patients with higher than median EGF concentrations in serum. Both Rodriquez et al and
Vinageras et al found a survival advantage in vaccinated patients with good antibody response as
determined by each trial’s criteria which was statistically significant in Rodrigues et al however
no mention of statistical significance was made by Vinageras et al.6,7 Kananathan et al made no
claims regarding efficacy as is appropriate since this study is an observational, not experimental
study and therefore no claims about efficacy can be made from such a study. The authors simply
comment that Phase III clinical trial results are necessary to determine efficacy.8
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In terms of safety, all three studies determined the vaccine to be well tolerated.6,7,8
Interestingly, for the Rodriguez et al study, the NNH was lower than the NNT but the types of
reported side effects would generally be considered reactions that do not threaten mortality or
significantly affect overall quality of life as compared to the advantage of overall survival.
Limitations of Evidence
Both Rodriguez et al and Vinageras et al used the Kaplan Meier method to estimate
survival time and the standard log-rank test to compare survival between the vaccine and control
groups which are appropriate and common for this type of data.
In Rodriguez et al, the small horizontal distances between data points in the Kaplan
Meyer curves for survivorship indicate a large number of enrolled subjects suggesting the sample
size is more likely to represent the true population. There are also a considerable number of
censored subjects in these curves which indicates that the survivorship estimates may not be that
accurate. Censored patients were not shown for the survivorship curves in the high EGF serum
concentration subpopulation and no reason was given as to why which limits the reliability of
this data. There is overlap of the confidence intervals (CIs) for median survival in months for the
vaccinated and control groups in the entire population studied as well as in the subpopulation of
patients with higher than median EGF serum concentrations, indicating that the true population
median in the vaccinated and control groups is possibly the same or median survival is higher in
the control group than in the vaccine group. The median survivals are however a snapshot in
time and survival differences over time are best compared with the log rank test the results of
which showed the data to be statistically significant. The CI for the hazard ratio (HR) (95% CI
0.61-0.98) however indicates that the risk of death for vaccinated patients could be very close to
the risk of death for control patients at any point in time (if population HR was 0.98). In the
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subgroup of patients with higher than median EGF serum concentrations, CIs for median
survival for both the vaccine and control groups were quite wide indicating a wide variability in
overall survival within the group and/or a very small number of patients in this group. No CIs for
median survival in months was reported for vaccinated patients with good antibody response as
compared to the control group. It is important to keep in mind though that the vaccine and
control group were not equal in terms of number of patients studied for efficacy, with about
2/3rds of the total number of patients studies for efficacy belonging to the vaccine arm and only
1/3rd belonging in the control arm.
In the Vinageras et al study, censored patients are indicated in all the survivorship curves,
and the number of censored patients appear to be few, however, this is a much smaller study than
the Rodriguez et al study so to some extent that is expected. No CIs are reported for median
survival in months, however both medians and means are reported. There was a large difference
between the mean and medians of both the vaccinated and control groups when measuring
survival in months for all patients indicating there are one or more outliers in the group that skew
some of the date in the direction of increased survival.
CONCLUSION
Although both RCTs claimed EGF vaccine to be effective in improving overall survival
in patients with NSCLC, there is insufficient evidence to claim EGF vaccine is effective in
improving survival because besides the obvious fact that this review only studies a very small
number of studies, there are problems with the study designs (risk of bias) and quality of the
evidence (nonreporting of censored patients, median survival CIs). Suggestions for future studies
would be designing double blind randomized control trials. In the United States, the first Phase
I/II randomized control trial is currently underway in the Roswell Park Cancer Institute.9
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